Editorial

Introducing our Chief Medical Editors

Welcome to the second issue of HCV Next.

In this issue, you will read an in-depth cover story with expert opinion on the controversial costs of care surrounding implementation of the new approved direct-acting antiviral therapies. The feature article explores the debate between risk-based and universal HCV screening recommendations for baby boomers. HCV Next Editorial Board member Catherine T. Frenette, MD, and colleagues present an interesting Case Challenge about a patient with unique adverse events after receiving interferon therapy; Douglas T. Dieterich, MD, answers 5 questions about his life in and out of the office; and three HCV Next Editorial Board members provide their take on the most interesting news from CROI 2014.

Ira M. Jacobson

As you are aware, it is an exciting time to be involved in the care of patients with HCV. Paradigm-changing therapies seem to be evolving on a daily basis, and we at HCV Next have made it our mission to be on top of the trends and news that matter most to your practice.

Achieving this goal would not be possible without the relationships our editorial staff has developed with key researchers in the field, as well as the input and contributions from our Editorial Board of experts. With this issue, we welcome our new Co-Chief Medical Editors: Ira M. Jacobson, MD, and Michael S. Saag, MD.

Michael S. Saag

Dr. Jacobson is chief of the division of gastroenterology and hepatology and Vincent Astor distinguished professor of medicine at the Joan Sanford I. Weill Medical College of Cornell University; attending physician at New York-Presbyterian Hospital Cornell Campus; and medical director of the Center for the Study of Hepatitis C. He has been a principal investigator on many key studies in emerging treatments for HCV.

Dr. Saag is professor of medicine, Jim Straley Chair in AIDS Research and director of the Center for AIDS Research at the University of Alabama at Birmingham. He is a past chair of the HIV Medicine Association and is published frequently in peer-reviewed journals and textbooks on the topic of patients with HIV who also have HCV, chronic kidney disease and other comorbidities.

Together, Drs. Jacobson and Saag bring a wealth of expertise and experience to HCV Next, spanning hepatology, infectious diseases and gastroenterology. In the spirit of collaboration, their joint involvement will assure that the needs of clinicians from varying disciplines are met in each issue. Together, let’s welcome Drs. Jacobson and Saag to HCV Next.

— Katie Kalvaitis
Executive Editor, HCV Next
kkalvaitis@slackinc.com

Welcome to the second issue of HCV Next.

In this issue, you will read an in-depth cover story with expert opinion on the controversial costs of care surrounding implementation of the new approved direct-acting antiviral therapies. The feature article explores the debate between risk-based and universal HCV screening recommendations for baby boomers. HCV Next Editorial Board member Catherine T. Frenette, MD, and colleagues present an interesting Case Challenge about a patient with unique adverse events after receiving interferon therapy; Douglas T. Dieterich, MD, answers 5 questions about his life in and out of the office; and three HCV Next Editorial Board members provide their take on the most interesting news from CROI 2014.

Ira M. Jacobson

As you are aware, it is an exciting time to be involved in the care of patients with HCV. Paradigm-changing therapies seem to be evolving on a daily basis, and we at HCV Next have made it our mission to be on top of the trends and news that matter most to your practice.

Achieving this goal would not be possible without the relationships our editorial staff has developed with key researchers in the field, as well as the input and contributions from our Editorial Board of experts. With this issue, we welcome our new Co-Chief Medical Editors: Ira M. Jacobson, MD, and Michael S. Saag, MD.

Michael S. Saag

Dr. Jacobson is chief of the division of gastroenterology and hepatology and Vincent Astor distinguished professor of medicine at the Joan Sanford I. Weill Medical College of Cornell University; attending physician at New York-Presbyterian Hospital Cornell Campus; and medical director of the Center for the Study of Hepatitis C. He has been a principal investigator on many key studies in emerging treatments for HCV.

Dr. Saag is professor of medicine, Jim Straley Chair in AIDS Research and director of the Center for AIDS Research at the University of Alabama at Birmingham. He is a past chair of the HIV Medicine Association and is published frequently in peer-reviewed journals and textbooks on the topic of patients with HIV who also have HCV, chronic kidney disease and other comorbidities.

Together, Drs. Jacobson and Saag bring a wealth of expertise and experience to HCV Next, spanning hepatology, infectious diseases and gastroenterology. In the spirit of collaboration, their joint involvement will assure that the needs of clinicians from varying disciplines are met in each issue. Together, let’s welcome Drs. Jacobson and Saag to HCV Next.

— Katie Kalvaitis
Executive Editor, HCV Next
kkalvaitis@slackinc.com